Herantis Pharma: xCDNF Candidate Selection – Check
Herantis Pharma announced today that the company has selected HER-096 as lead candidate for its non-invasive xCNDF program. We give our take on the positive news.
FT
Fredrik Thor
Disclosures and disclaimers